viewAIM ImmunoTech Inc.

Medsea Estates Group - Directorate Change

RNS Number:3440I Medsea Estates Group PLC 23 November 2007 Medsea Estates Group plc ('Medsea' or 'the Company') Board Appointment Medsea Estates Group plc (AIM: MEA), the Mediterranean-based property group, is pleased to announce the appointment of Neil Emmet Craven as a non-executive director with effect from 1st December 2007. Mr Craven holds 1 million shares in the Company representing 1.3% of the issued shares. Neil Craven, 39, has many years' experience at senior management levels in telecommunications and fund management. He was part of the founding management team of Carrier1 International S.A., a NASDAQ-listed pan-European provider of telecoms services to internet service providers and other telecom companies where he served as vice-president in charge of business development from 1998 to 2003. During this time, he was also responsible for the pan-European broadband business and for capital expenditure across the group. In 2003, he moved into fund management and from late 2004 to the end of 2006 he was a partner in a Swiss-based asset management and corporate finance boutique where he was responsible for establishing and managing a hedge fund focussed on special situations and small cap equities. He is currently a private investor focusing on small-cap equities. He holds a degree in computer engineering from Trinity College Dublin and an MBA from the Rotterdam School of Management. - Ends - For further information: Medsea Estates Group plc Tony Gatehouse, Chairman Tel: +34 96 570 40 02 Juan Carlos Rodriguez Martinez, Chief Executive HB Corporate Edward Hutton / Rachel Kane/Imran Ahmad Tel: +44 (0) 20 7510 8600 Media enquiries: Threadneedle Communications Alex White/Josh Royston Tel: +44 (0) 20 7936 9665 Appendix re AIM Rules requirements: In the last five years, Mr Craven was a partner of Azemos Partner AG (October 2004 to December 2006) and managing director of Carrier1 International GmbH ('GmbH'), the Swiss subsidiary of Carrier1 International S.A (January 2002 to February 2003). He was appointed to the latter role shortly before GmbH filed for protection from creditors resulting from Carrier1 International S.A.'s filing for insolvency in February 2002. In that role, he led the liquidation of the group's assets and businesses as well as the reduction of its liabilities. The insolvency resulted from the inability of Carrier1 International S.A. (for technical reasons under Luxembourg law) to proceed with a financial restructuring with bondholders. There is no further information to disclose in accordance with Schedule Two (g) of the AIM Rules. This information is provided by RNS The company news service from the London Stock Exchange END BOAPUGCWGUPMGMP

Quick facts: AIM ImmunoTech Inc.

Price: 0.4851

Market: NYSE
Market Cap: $2.35 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Hemispherx Biopharma releases 'well tolerated' data for...

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) CEO Thomas Equels tells Protactive that a final report on its phase 1 trial supporting the safety of using its flagship drug Ampligen as a combination therapy to treat recurrent ovarian cancer found that it was “well tolerated." Equels explains the...

on 08/19/2019